Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-debate-20260410-112400-454036f1_20260416-035530",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: CD8+ T Cell Dichotomy in Neurodegeneration\n\n---\n\n## 1. Translational Potential Assessment\n\n### Tier 1: Highest Potential\n\n**Hypothesis 1 (Temporal Clonal Replacement)**, despite the Skeptic's valid critique, remains the most translationally actionable because it proposes a **finite, targetable recruitment pathway** (CXCR3-mediated infiltration). The therapeutic angle—preventing pathogenic recruitment rather than depleting all CD8+ T cells—is strategically sound given the likely protective role of these cells in viral surveillance. This fits within an emerging therapeutic paradigm of \"immune normalization\" rather than broad immunosuppression.\n\n**Hypothesis incorporating antigen specificity** (drawn from the Skeptic's counter-evidence): Klein et al. establishes that the *same differentiation phenotype* can be protective or pathogenic depending on antigen recognition. This reframes the therapeutic question: rather than targeting CD8+ T cells globally, we need to identify and selectively modulate those reactive against neuronal antigens while preserving beneficial antiviral immunity. This has the highest safety profile of all options.\n\n### Tier 2: Moderate Potential\n\n**Hypothesis 2 (Exhaustion phenotype as pathological state):** The Dulken et al. data suggesting CD8+ T cells adopt an \"adapted exhaustion\" state in aged brain is mechanistically important but less immediately actionable. Checkpoint blockade approaches (anti-PD-1/LAG-3) carry substantial safety concerns in elderly populations with AD (autoimmune toxicity, amyloid-related imaging abnormalities). However, this hypothesis generates an important negative prediction: global T cell activation would be harmful, not beneficial.\n\n---\n\n## 2. Clinical Evidence, Safety, and Patient Population Fit\n\n### Hypothesis 1 (CXCR3 blockade to prevent pathogenic recruitment)\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Current Clinical Evidence** | Indirect only. CXCR3 antagonists are in clinical development for autoimmune conditions (MS, psoriasis) but no AD trials. Historical failure of anti-inflammatory approaches in AD creates reasonable skepticism. |\n| **Safety Considerations** | Moderate-to-favorable. CXCR3 blockade is more selective than global immunosuppression; the primary risk is impaired defense against intracellular pathogens (viral reactivation). This is manageable with patient selection. |\n| **Patient Population Fit** | Early-stage AD or prodromal MCI. The therapeutic window is early because the model posits a temporal transition. Patients with biomarker evidence of active neuroinflammation (elevated CSF YKL-40, IL-6) may be optimal candidates. The overlap with anti-amyloid antibody trials is complementary but creates combination-trial complexities. |\n\n### Antigen-Specific Modulation Hypothesis\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Current Clinical Evidence",
  "tokens_used": "730"
}